{"pmid":32243877,"title":"Running a virtual allergy division and training program in the time of COVID-19 pandemic.","text":["Running a virtual allergy division and training program in the time of COVID-19 pandemic.","J Allergy Clin Immunol","Codispoti, Christopher D","Bandi, Sindhura","Moy, James","Mahdavinia, Mahboobeh","32243877"],"journal":"J Allergy Clin Immunol","authors":["Codispoti, Christopher D","Bandi, Sindhura","Moy, James","Mahdavinia, Mahboobeh"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243877","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaci.2020.03.018","keywords":["Covid-19","allergy division","pandemic","training program","virtual"],"source":"PubMed","weight":0,"_version_":1663079112920530944,"score":7.6048946,"similar":[{"pmid":32224232,"title":"COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","text":["COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so.","J Allergy Clin Immunol Pract","Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew","32224232"],"abstract":["In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so."],"journal":"J Allergy Clin Immunol Pract","authors":["Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224232","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaip.2020.03.012","keywords":["Allergic rhinitis","Allergy","Allergy immunotherapy","Angioedema","Asthma","Atopic dermatitis","COVID-19","Food allergy","Primary immunodeficiency","SARS-CoV-2","Urticaria","Venom allergy"],"source":"PubMed","locations":["Canada","United States"],"countries":["Canada","United States"],"countries_codes":["CAN|Canada","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1662819280347987968,"score":46.42008},{"pmid":32153144,"title":"COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis.","text":["COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis.","Infect Chemother","Song, Young Goo","Shin, Hyoung Shik","32153144"],"journal":"Infect Chemother","authors":["Song, Young Goo","Shin, Hyoung Shik"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32153144","week":"202011|Mar 09 - Mar 15","keywords":["*COVID-19","*Coronavirus","*SARS-CoV-2","*Hypersensitivity pneumonitis"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543852470273,"score":41.587307},{"pmid":32160451,"title":"Virtually Perfect? Telemedicine for Covid-19.","text":["Virtually Perfect? Telemedicine for Covid-19.","N Engl J Med","Hollander, Judd E","Carr, Brendan G","32160451"],"journal":"N Engl J Med","authors":["Hollander, Judd E","Carr, Brendan G"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32160451","week":"202011|Mar 09 - Mar 15","doi":"10.1056/NEJMp2003539","source":"PubMed","weight":0,"_version_":1662334543795847169,"score":41.290638},{"pmid":32217506,"title":"The Role of the Global Health Development/Eastern Mediterranean Public Health Network and the Eastern Mediterranean Field Epidemiology Training Programs in Preparedness for COVID-19.","text":["The Role of the Global Health Development/Eastern Mediterranean Public Health Network and the Eastern Mediterranean Field Epidemiology Training Programs in Preparedness for COVID-19.","The World Health Organization (WHO) declared the current COVID-19 a public health emergency of international concern on January 30, 2020. Countries in the Eastern Mediterranean Region (EMR) have a high vulnerability and variable capacity to respond to outbreaks. Many of these countries addressed the need for increasing capacity in the areas of surveillance and rapid response to public health threats. Moreover, countries addressed the need for communication strategies that direct the public to actions for self- and community protection. This viewpoint article aims to highlight the contribution of the Global Health Development (GHD)/Eastern Mediterranean Public Health Network (EMPHNET) and the EMR's Field Epidemiology Training Program (FETPs) to prepare for and respond to the current COVID-19 threat. GHD/EMPHNET has the scientific expertise to contribute to elevating the level of country alert and preparedness in the EMR and to provide technical support through health promotion, training and training materials, guidelines, coordination, and communication. The FETPs are currently actively participating in surveillance and screening at the ports of entry, development of communication materials and guidelines, and sharing information to health professionals and the public. However, some countries remain ill-equipped, have poor diagnostic capacity, and are in need of further capacity development in response to public health threats. It is essential that GHD/EMPHNET and FETPs continue building the capacity to respond to COVID-19 and intensify support for preparedness and response to public health emergencies.","JMIR Public Health Surveill","Al Nsour, Mohannad","Bashier, Haitham","Al Serouri, Abulwahed","Malik, Elfatih","Khader, Yousef","Saeed, Khwaja","Ikram, Aamer","Abdalla, Abdalla Mohammed","Belalia, Abdelmounim","Assarag, Bouchra","Baig, Mirza Amir","Almudarra, Sami","Arqoub, Kamal","Osman, Shahd","Abu-Khader, Ilham","Shalabi, Dana","Majeed, Yasir","32217506"],"abstract":["The World Health Organization (WHO) declared the current COVID-19 a public health emergency of international concern on January 30, 2020. Countries in the Eastern Mediterranean Region (EMR) have a high vulnerability and variable capacity to respond to outbreaks. Many of these countries addressed the need for increasing capacity in the areas of surveillance and rapid response to public health threats. Moreover, countries addressed the need for communication strategies that direct the public to actions for self- and community protection. This viewpoint article aims to highlight the contribution of the Global Health Development (GHD)/Eastern Mediterranean Public Health Network (EMPHNET) and the EMR's Field Epidemiology Training Program (FETPs) to prepare for and respond to the current COVID-19 threat. GHD/EMPHNET has the scientific expertise to contribute to elevating the level of country alert and preparedness in the EMR and to provide technical support through health promotion, training and training materials, guidelines, coordination, and communication. The FETPs are currently actively participating in surveillance and screening at the ports of entry, development of communication materials and guidelines, and sharing information to health professionals and the public. However, some countries remain ill-equipped, have poor diagnostic capacity, and are in need of further capacity development in response to public health threats. It is essential that GHD/EMPHNET and FETPs continue building the capacity to respond to COVID-19 and intensify support for preparedness and response to public health emergencies."],"journal":"JMIR Public Health Surveill","authors":["Al Nsour, Mohannad","Bashier, Haitham","Al Serouri, Abulwahed","Malik, Elfatih","Khader, Yousef","Saeed, Khwaja","Ikram, Aamer","Abdalla, Abdalla Mohammed","Belalia, Abdelmounim","Assarag, Bouchra","Baig, Mirza Amir","Almudarra, Sami","Arqoub, Kamal","Osman, Shahd","Abu-Khader, Ilham","Shalabi, Dana","Majeed, Yasir"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217506","week":"202013|Mar 23 - Mar 29","doi":"10.2196/18503","keywords":["COVID-19","outbreak","preparedness","public health","response"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1662540582150471681,"score":41.00689},{"pmid":32233018,"title":"Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.","text":["Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.","A novel RNA betacoronavirus causing coronavirus disease 2019 (Covid-19) has now been declared pandemic disease by WHO. Guo W et al published the first report of biochemical features in patients with diabetes and the further risk that this disease can determine to the progression of Covid-19. Among different cytokines found significantly higher in patients with diabetes compared to those without, Interleukin-6 (IL-6) which is already increased in conditions of chronic inflammation, may play a more deleterious role in Covid-19 infection. Targeting the over expression of Il-6 effects with a monoclonal antibody against IL-6 receptor or using Janus Kinase inhibitors may be particularly helpful for treatment of Covid-19 pneumonia in diabetes. This article is protected by copyright. All rights reserved.","Diabetes Metab Res Rev","Maddaloni, Ernesto","Buzzetti, Raffaella","32233018"],"abstract":["A novel RNA betacoronavirus causing coronavirus disease 2019 (Covid-19) has now been declared pandemic disease by WHO. Guo W et al published the first report of biochemical features in patients with diabetes and the further risk that this disease can determine to the progression of Covid-19. Among different cytokines found significantly higher in patients with diabetes compared to those without, Interleukin-6 (IL-6) which is already increased in conditions of chronic inflammation, may play a more deleterious role in Covid-19 infection. Targeting the over expression of Il-6 effects with a monoclonal antibody against IL-6 receptor or using Janus Kinase inhibitors may be particularly helpful for treatment of Covid-19 pneumonia in diabetes. This article is protected by copyright. All rights reserved."],"journal":"Diabetes Metab Res Rev","authors":["Maddaloni, Ernesto","Buzzetti, Raffaella"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32233018","week":"202014|Mar 30 - Apr 05","doi":"10.1002/dmrr.3321","keywords":["Covid-19","Diabetes","Inflammation; IL-6"],"source":"PubMed","locations":["Janus"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1662899337716301824,"score":40.295452}]}